Context Studies of long-term hormone replacement therapy
(HRT) suggest an associated increased risk of breast cancer,
but whether this association differs according to histologic
type of cancer has not been extensively studied.
Objective To determine whether the association between
HRT and risk of breast cancer varies by HRT formulation and
differs across histologic cancer types.
Design, Setting, and Participants Nested case-control
study among 705 postmenopausal women enrolled in the Group Health
Cooperative of Puget Sound (GHC) who were aged 50 to 74 years
and had primary invasive breast cancer diagnosed between July
1, 1990, and December 31, 1995 (cases), and 692 randomly selected
aged-matched female members of GHC (controls).
Main Outcome Measure Incidence and type of breast cancer
by duration of HRT use in the 5-year period ending 1 year before
diagnosis, which was ascertained from computerized pharmacy
records.
Results The incidence of breast cancer, all histologic
types combined, was increased by 60% to 85% in recent long-term
users of HRT, whether estrogen alone or estrogen plus progestin.
Longer use of HRT (odds ratio [OR], 3.07 for 57 months or more;
95% confidence interval [CI], 1.55-6.06) and current use of
combination therapy (OR, 3.91; 95% CI, 2.05-7.44) were associated
with increased risk of lobular breast cancer. Long-term HRT
use was associated with a 50% increase in nonlobular cancer
(OR, 1.52 for 57 months or more; 95% CI, 1.01-2.29).
Conclusion Our data add to the growing body of evidence
that recent long-term use of HRT is associated with an increased
risk of breast cancer and that such use may be related particularly
to lobular tumors.
相似文献